--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About TARA20260515C5
Biological Technology
Protara Therapeutics, Inc., was originally incorporated in Delaware on March 24, 2006. The company is a clinical-stage biopharmaceutical company based in New York City that advances transformative therapies for the treatment of cancer and rare diseases. The company's product portfolio includes two development projects utilizing TARA-002, an investigational cell therapy based on the broad immune-enhancing agent OK-432, which was originally granted marketing authorization by the Ministry of Health and Welfare of Japan as an immune-enhancing cancer treatment agent.
